PFM Health Sciences LP Invests $2.23 Million in ARK Genomic Revolution ETF (BATS:ARKG)

PFM Health Sciences LP purchased a new stake in ARK Genomic Revolution ETF (BATS:ARKG) during the third quarter, Holdings Channel.com reports. The institutional investor purchased 86,934 shares of the company’s stock, valued at approximately $2,226,000.

Several other institutional investors also recently bought and sold shares of the company. First Horizon Advisors Inc. grew its holdings in shares of ARK Genomic Revolution ETF by 9.4% during the second quarter. First Horizon Advisors Inc. now owns 4,650 shares of the company’s stock worth $109,000 after buying an additional 398 shares in the last quarter. Crescent Grove Advisors LLC grew its stake in ARK Genomic Revolution ETF by 1.6% during the 3rd quarter. Crescent Grove Advisors LLC now owns 28,914 shares of the company’s stock valued at $740,000 after acquiring an additional 460 shares in the last quarter. Prospect Financial Services LLC raised its holdings in ARK Genomic Revolution ETF by 3.7% in the 2nd quarter. Prospect Financial Services LLC now owns 14,093 shares of the company’s stock valued at $331,000 after acquiring an additional 500 shares during the last quarter. Bridges Investment Management Inc. lifted its stake in ARK Genomic Revolution ETF by 3.8% in the 2nd quarter. Bridges Investment Management Inc. now owns 14,121 shares of the company’s stock worth $332,000 after purchasing an additional 517 shares in the last quarter. Finally, Brown Miller Wealth Management LLC boosted its holdings in shares of ARK Genomic Revolution ETF by 5.5% during the 3rd quarter. Brown Miller Wealth Management LLC now owns 17,974 shares of the company’s stock worth $460,000 after purchasing an additional 933 shares during the last quarter.

ARK Genomic Revolution ETF Stock Up 2.0 %

ARKG stock opened at $25.95 on Friday. The firm has a 50-day moving average of $24.60 and a 200 day moving average of $25.12.

ARK Genomic Revolution ETF Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.